Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Separation Science



View Channel

Microscopy | Image Analysis



View Channel

IT Solutions and Laboratory Automation



View Channel


Conferences | Events

Exothera announces a strategic partnership with Quantoom Biosciences and launches a new business unit for the development and production of RNA

publication date: May 26, 2023
author/source: Exothera



Exothera Nucleic Acids will be the world’s first CDMO with access to Quantoom’s revolutionary Nfinity™ platform for the continuous production of RNA which Exothera will offer as a service

Exothera has partnered with Quantoom Biosciences ("Quantoom") to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in terms of efficiency, productivity, quality control, cost-effectiveness, and scalability.

Exothera will provide the service through a new business unit, Exothera Nucleic Acids, that focuses on accelerating the process development and manufacturing of RNA vaccines and therapeutics.

Combining Exothera’s development and manufacturing expertise with Quantoom’s continuous biomanufacturing platform will allow biotech and pharma companies to simplify RNA vaccine development and accelerate their clinical and commercial timelines. By leveraging the Nfinity technology, Exothera will offer development services, non GMP and GMP manufacturing as well as analytical services to pharma/biotech for mRNA and saRNA therapeutic development.

Thibault Jonckheere, CEO of Exothera, commented, "The market potential for RNA therapies continues to grow and expand into new therapeutic areas, but the process of developing a new RNA vaccine or therapeutic is hindered by outdated technology that was never intended to scale for commercialization. We are thrilled to not only announce the launch of our new business unit focused on nucleic acids, but also our strategic collaboration with Quantoom Biosciences. This collaboration enables Exothera to make the highest quality RNA for vaccines and therapeutics with low-risk process development and almost guaranteed product quality from sequence up to mass production in a much shorter time than previously possible."

"We're thrilled by this new partnership which marks a new milestone for Quantoom, added José Castillo, CEO of Quantoom. "The advantages of continuous manufacturing for RNA are clear, and we believe this partnership will provide significant benefits to biotech and pharma companies developing RNA vaccines and therapeutics. By combining Exothera's expertise with our cutting-edge platform, we can simplify the process and accelerate timelines for RNA development and production. We're excited to see the impact this partnership will have on the industry and ultimately, on patients' lives."

Exothera’s services will be available to biotech and pharmaceutical companies of all sizes and stages of development whether they are starting from a known protein sequence (antigen) or have a product in pre-clinical development or clinical trials. The company is currently accepting inquiries for its services and is actively seeking partnerships with biotech and pharmaceutical companies to support their drug development programs.


About Exothera

Exothera is a contract research, development, and manufacturing organization (CRDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services and process development/optimization to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. The mission of Exothera and Univercells is to make life-changing therapies available to all.


About Quantoom Biosciences

Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity™) that encompasses DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™), along with critical reagent supply, from sequence to large scale production. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. We are part of Univercells, a global life sciences group that makes biologics available to all.



Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners